UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

~~of the~~ Securities Exchange Act of 1934

Date of ~~Report~~report (Date of earliest event reported): ~~September~~November 2613, 2025

STRATA SKIN SCIENCES, INC.

(Exact ~~name~~Name of ~~registrant~~Registrant asSpecified ~~specified~~ in ~~its~~ Charter)

Delaware	000-51481	~~000~~13-~~51481~~3986004	~~13-3986004~~
(State or other jurisdiction of incorporation)		(Commission File Number)	(IRS Employer Identification No.)
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

5 Walnut Grove Drive, Suite 140

5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania		19044
(Address of Principal Executive Offices)		(Zip Code)

~~Horsham~~Registrant's telephone number, ~~Pennsylvania~~including ~~19044~~area code: 215-619-3200

(Former Name or Former Address, ofif ~~principal~~Changed ~~executive~~Since ~~offices)~~Last ~~(Zip Code~~Report)

~~215~~Check the appropriate box below if the Form 8-~~619-3200~~K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	~~Trading~~Name ~~Symbol(s)~~of each exchange on which registered	~~Name of each exchange on which registered~~
Common Stock, $0,001 par value per share		SSKN	The Nasdaq Stock Market LLC
Common Stock, $0.001 par value per share	SSKN	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 82.0102. ~~Other~~Results ~~Events~~of Operations and Financial Condition.

AsOn ~~previously~~November ~~reported~~13, 2025, STRATA Skin Sciences, Inc. (the “Company”) ~~entered into an equity distribution agreement (the “Equity Distribution Agreement”)~~ ~~dated~~ issued ~~October~~a ~~15,~~press ~~2021,~~release ~~with~~announcing ~~Ladenburg~~its ~~Thalmann~~results &of ~~Co.~~operations ~~Inc.~~ for the ~~issuance~~third ~~and~~fiscal ~~sale~~quarter inended ~~registered~~September ~~“at-the-market” offerings of up to $11.0 million in shares of the Company’s common stock~~31, ~~par value $0~~2025.~~001~~ ~~per share (the “Shares”).~~ The ~~Shares were~~full ~~initially~~text ~~registered~~of on a Registration Statement on Form S-3 (File No. 333-258814) initially filed by the Company with the Securities and Exchange Commission (the “Commission”) under the Securities Act on August 13, 2021, and declared effective by the Commission on October 15, 2021 (together with the amendment thereto, the “Initial Registration Statement”), and such ~~Initial~~ ~~Registration~~press ~~Statement,~~release ~~including registration of the Shares, has been replaced by that Registration Statement on Form S-3 (File~~is ~~No. 333-283418)~~ furnished ~~initially~~as ~~filed~~Exhibit by the Company with the Commission under the Securities Act on November 22, 2024 and declared effective by the Commission on December 18, 2024 (together with the amendment thereto, the “Registration Statement”)99.1 ~~The Company has filed with the Commission a prospectus supplement~~ to ~~the~~this ~~prospectus contained in the Registration Statement, dated September 26, 2025, as may be amended from time to time, in connection with the offer and sale of the Shares in the future~~report.

InThe ~~connection~~information ~~with~~set ~~the~~forth ~~Equity Distribution~~under ~~Agreement~~this Item 2.02, ~~the~~including ~~Company~~Exhibit 99.1, is ~~filing~~being asfurnished ~~Exhibits~~and ~~5.1~~shall ~~and~~not ~~23.1~~be ~~hereto~~deemed an“filed” ~~opinion~~for the purposes of ~~its~~Section ~~counsel,~~18 ~~Stevens &~~of ~~Lee~~the Securities Exchange Act of 1934, ~~P.C.~~as amended (the “Exchange Act”), ~~with~~ ~~respect~~or otherwise subject to the ~~legality~~liabilities of ~~the~~such ~~Shares~~section, ~~which~~nor ~~are~~shall such information be deemed incorporated ~~herein~~by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

~~This~~Item ~~Current~~7.01. ~~Report~~Regulation onFD Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such stateDisclosure.

~~Item~~On 9November 13, 2025, STRATA Skin Sciences, Inc.01 ~~Financial~~(the ~~Statements~~“Company”) ~~and~~issued ~~Exhibits~~a press release announcing its results of operations for the third fiscal quarter ended September 31, 2025. The full text of such press release is furnished as Exhibit 99.1 to this report.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (dthe “Exchange Act”), ~~Exhibits:~~or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

	5.1	Opinion of Stevens & Lee, P.C.
	23.1	Consent of Stevens & Lee, P.C. (included in Exhibit 5.1)
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Item 9.01.

Financial Statements and Exhibits.

1(d) Exhibits.

~~SIGNATURES~~The following press release is furnished as an exhibit to this Current Report on Form 8-K pursuant to Item 2.02 and shall not be deemed to be “filed”:

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	99.1	Press Release dated November 13, 2025 issued by STRATA Skin Sciences, Inc.
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

	STRATA SKIN SCIENCES, INC.
Dated: October 16, 2025	By:	/s/ John Gillings
		John Gillings
		Chief Accounting Officer

SIGNATURE

2Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	STRATA SKIN SCIENCES, INC.

Date: November 13, 2025	By:	/s/ John Gillings

		Chief Accounting Officer

Filing Compare · STRATA Skin Sciences, Inc.